Search
The results of your search are listed below. To view the details of a trial or study, click on the "SEE DETAILS" button. Or start a new search.
Searched for: ovarian. 17 results shown below.
Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer
Complete title: Lavage of the Uterine Cavity for Diagnosis of Ovarian Carcinomas
Principal Investigator: Barbara Norquist, MD
Study Number: 10019
Phase: N/A
The Effects of Moderate Exercise on Distress, Quality of Life, and Biomarkers of Angiogenesis and Chronic Stress in Ovarian Cancer Survivors
Complete title: The Effects of Moderate Exercise on Distress, Quality of Life, and Biomarkers of Angiogenesis and Chronic Stress in Ovarian Cancer Survivors
Principal Investigator: Kathryn Pennington
Study Number: 10045
Phase: N/A
Olaparib In Metastatic Breast Cancer
Complete title: A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes "Olaparib Expanded"
Principal Investigator: Shaveta Vinayak
Study Number: TBCRC048
Phase: II
Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Complete title: Phase I Study Evaluating Benefit of PRGN-3005 (Autologous CAR T Cells) Delivered by Intraperitoneal Infusion (IP) or Intravenous Infusion (IV) in Advanced Stage Platinum Resistant Ovarian Cancer Patients
Principal Investigator: John Liao, MD, PhD
Study Number: 10056
Phase: I
Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Complete title: AGCT1531, Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
Principal Investigator: Abby Rosenberg
Study Number: AGCT1531
Phase: III
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian or Primary Peritoneal Cancer
Complete title: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Principal Investigator: Heidi Gray, MD
Study Number: RG1006416
Phase: III
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Complete title: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Principal Investigator: Heidi Gray, MD
Study Number: S1609
Phase: II
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
Complete title: A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients with Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma
Principal Investigator: Sylvia Lee, MD
Study Number: 10501
Phase: I
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Complete title: A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Principal Investigator: Elizabeth Loggers
Study Number: 9612
Phase: II
A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors
Complete title: A Multi-Center, Open Label Phase 1/2 Study of CYT-0851, An Oral RAD51 Inhibitor, In Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
Principal Investigator: Ryan Lynch
Study Number: RG1006339
Phase: I/II
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Complete title: A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF-06940434 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS
Principal Investigator: John Thompson, MD
Study Number: RG1006384
Phase: I
Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian (PROFECTA-II)
Complete title: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer
Principal Investigator: John Liao, MD, PhD
Study Number: RG1007197
Phase: II
A Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Study of PF-06873600 as a Single Agent and in Combination With Endocrine Therapy
Complete title: PHASE 1/2a DOSE ESCALATION AND EXPANSION STUDY
EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETIC,
PHARMACODYNAMICS AND ANTI-TUMOR ACTIVITY OF
PF-06873600 AS A SINGLE AGENT AND IN COMBINATION WITH
ENDOCRINE THERAPY
Principal Investigator: Shaveta Vinayak
Study Number: RG1007255
Phase: I/II
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
Complete title: A Phase 1b/2, Multicenter, Open-Label Study of DSP-7888 Dosing Emulsion in Combination with Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Adult Patients with Advanced Solid Tumors
Principal Investigator: John Liao, MD, PhD
Study Number: RG1007497
Phase: I/II
PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
Complete title: A Multicenter, Open-Label, Parallel, Phase 2a Study of PLX2853 Monotherapy in Advanced Gynecological Malignancies with a Known ARID1A Mutation and Phase 1b/2a Study of PLX2853/Carboplatin Combination Therapy in Platinum-Resistant Epithelial Ovarian Cancer
Principal Investigator: Elizabeth Swisher, MD
Study Number: RG1007920
Phase: I/II
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
Complete title: Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies
Principal Investigator: Gabriela Chiorean
Study Number: RG1121312
Phase: N/A
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Complete title: SC-4008, EZH-202, A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Principal Investigator: Erin Pinto
Study Number: SC-4008
Phase: II